ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Phase I/II study (NCT02885766) of this agent is recruiting patients with Ph‐positive CML whose disease is resistant to the second‐generation ABL1 inhibitors or has T315I mutation in the BCR–ABL gene.